جستجوی استاد راهنمای دانشگاهی

Prof. Dr. A. Jeyaprakash Arulanandam (JP) serves as Professor at the Gene Center and Department of Biochemistry, Ludwig Maximilian University of Munich, where his ERC Advanced Grant-funded laboratory commenced operations on March 1, 2023. Concurrently, he holds a Personal Chair of Structural Cell Biology and serves as Co-Head of the Institute of Cell Biology at the University of Edinburgh's Wellcome Centre for Cell Biology since 2022. His research employs an integrative structure-function approach combining cryoEM, crystallography, and cross-linking mass spectrometry with proteomics and cell biology to investigate centromere assembly, RNA modification activities, and spindle assembly mechanisms. Key focus areas include structural basis of centromere maintenance, Mis18 complex function in centromere inheritance, and error-free chromosome segregation pathways. Recent publications (2020-2024) demonstrate consistent structural biology methodologies applied to chromosome segregation mechanisms, with increasing emphasis on RNA-modification activities and centromere epigenetic regulation. The work bridges high-resolution structural insights with cellular functional validation. Major scientific awards include: ERC Advanced Grant (2023-2028) Wellcome Senior Research Fellowship (2017-2022) Wellcome Career Development Fellowship (2012-2016) Max-Planck Institute Junior Research Award (2008) Alexander von Humboldt Fellowship (2004-2005) He supervises doctoral researcher Ana Alves do Vale Marques and postdoctoral researchers Paula Sotelo Parrilla and Guangpu Xue, supported by major grants including the ERC Advanced Grant and historical Wellcome Trust funding. His labs at LMU's Gene Center (Room A4.68) and Edinburgh's Wellcome Centre for Cell Biology form a collaborative structural cell biology research environment focused on chromosome dynamics.

• Structural Biology
• Cell Biology
• Chromosome Segregation
• +۳ مورد دیگر

Dr. Jack Tan is a Principal Investigator at the MRC Translational Immune Discovery Unit within the Radcliffe Department of Medicine at the University of Oxford. He holds a DPhil and BSc (Hons), and serves as a Career Development Fellow at the Chinese-Academy of Medical Sciences-Oxford Institute. Dr. Tan is also a Fellow by Special Election at St Edmund Hall. His research is focused on developing next-generation protein nanoparticle-based vaccines and antibody therapeutics against infectious diseases, with particular emphasis on understanding how vaccine architecture influences immunogenicity and investigating mucosal vaccine immunity for respiratory pathogens like coronavirus. Dr. Tan's primary research interests encompass vaccine development, immunology, infectious diseases, protein nanoparticles, antibody therapeutics, and coronavirus research. His work is particularly notable for its focus on pan-sarbecovirus nanoparticle vaccines, where he is part of an international consortium (Oxford-Caltech-CPI-Ingenza) funded by the Coalition of Epidemics Preparedness Innovations (CEPI). His recent publications demonstrate a strong emphasis on influenza vaccines, SARS-CoV-2 research, protein nanoparticle technology, and the development of broad-spectrum antiviral approaches. Dr. Tan leads the Tan Group: Next-Generation Vaccines against Infectious Diseases, while also collaborating with the Townsend Group: Molecular Immunology. His research portfolio shows a clear trajectory toward developing vaccines that can provide cross-protection against multiple viral variants and related pathogens, with significant implications for pandemic preparedness. The work spans fundamental immunological mechanisms through to translational applications, with a particular focus on structural determinants of antibody function and novel vaccine platforms.

• Vaccine Development
• Infectious Diseases
• Immunology
• +۵ مورد دیگر

Lucia Moreira is a Postdoctoral Researcher in the Division of Cardiovascular Medicine at the University of Oxford's Medical Sciences Division. She is affiliated with Wolfson College and the Reilly Group, which focuses on molecular signalling in adverse myocardial remodelling and fibrosis. Dr. Moreira holds a DPhil in Medical Sciences and investigates molecular mechanisms of atrial fibrillation (AF), emphasizing calcitonin receptor signalling pathways in atrial remodelling. Her work aims to identify therapeutic targets to mitigate AF progression and improve patient outcomes through advanced understanding of structural and electrical remodelling processes. Recent publications reveal a multidisciplinary research trajectory spanning single-nucleus multi-omics, aging-related AF mechanisms, genetic variants in arrhythmias, and protease-mediated heart failure pathways. This work bridges molecular cardiology with translational applications, particularly in fibrosis and electrical remodelling. Dr. Moreira collaborates within the Reilly Group framework and may co-supervise students on projects related to cardiac remodelling. Research funding likely derives from major UK bodies including the British Heart Foundation and Medical Research Council, supporting investigations into novel therapeutic targets for cardiovascular diseases. The Reilly Group provides a dynamic research environment focused on molecular signalling pathways in cardiac pathology, offering opportunities for collaboration in fibrosis, remodelling, and arrhythmia mechanisms.

• Cardiovascular Medicine
• Molecular Cardiology
• Atrial Fibrillation
• +۳ مورد دیگر

Renske Vroomans is a Research Fellow at the Sainsbury Laboratory , University of Cambridge. She is a theoretical biologist specializing in evolutionary developmental biology (Evo-Devo) and computational modeling of biological processes. Her work focuses on how gene regulatory networks and dynamical processes shape the evolution of plant and animal development. PhD in Theoretical Biology and Bioinformatics, Utrecht University Postdoctoral research at University of Helsinki and Origins Center Her research explores patterns in developmental evolution, including: Evolution of multicellularity under selection pressures Role of gene networks in tissue morphogenesis Computational models for long-term plant evolution Recent publications highlight computational approaches to: Evolutionary dynamics of genome fragility and division of labor Multicellularity driven by spatial information integration Developmental constraints in plant organ evolution Scientific awards include the Gatsby Career Development Fellowship . Her group includes PhD students Steven Oud, Alexandre P Fernandes, and Research Assistant Pjotr van der Jagt.

• Computational Biology
• Evolutionary Developmental Biology (Evo-Devo)
• Plant Development
• +۵ مورد دیگر

Mark Ehrensberger is an Associate Professor in the Department of Biomedical Engineering at the University at Buffalo, State University of New York. He is also the Director of the Kenneth A. Krackow MD Orthopaedic Research Lab within the Orthopaedics division, where he focuses on translational research for orthopaedic implant improvement. PhD, Bioengineering, Syracuse University (2008) MS, Bioengineering, Syracuse University (2002) BS, Bioengineering, Syracuse University (2000) His research spans orthopaedic biomaterials and orthopaedic biomechanics , with specific emphasis on electrochemical surface interactions of metallic implants and innovative mechanical testing for tissue repair . He has pioneered methods for infection control via electrical stimulation and osseointegration enhancement. His 15 most recent publications highlight interdisciplinary work in electrochemical biofilm eradication, titanium corrosion resistance, and biomechanical stability analysis for shoulder and dental implants. Key trends include electrotherapy integration with antibiotics and computational modeling of implant microenvironments. Young Investigators Initiative, US Bone and Joint Decade (2008) Jeanette Wilkins Award, Musculoskeletal Infection Society (2015) Senior Teacher of the Year, School of Engineering and Applied Sciences, University at Buffalo (2022) Ehrensberger has secured over $2.3 million in grants, including awards from the Office of Naval Research and Congressionally Directed Medical Research Program. His lab, the Ehrensberger Orthopedic Research Group (EORG), collaborates with clinicians and engineers to develop technologies like the Electrochemical Sense and Respond Osseointegrated Prosthesis .

• Orthopaedic Biomaterials
• Orthopaedic Biomechanics
• Biofilm Prevention
• +۳ مورد دیگر

Raluca Mihaela Gordan serves as Adjunct Associate Professor in the Department of Biostatistics & Bioinformatics at Duke University and is a Member of the Duke Cancer Institute Division of Integrative Genomics. Her work bridges computational biology, genomics, and cancer research with significant contributions to understanding transcription factor mechanisms. Education Ph.D., Duke University, 2009 Research Focus Dr. Gordan's research centers on transcription factor dynamics and their role in DNA damage susceptibility, mutagenesis, and cancer development. Her lab employs computational genomics and high-throughput data modeling to investigate how transcription factor binding sites become mutation hotspots due to environmental exposures like UV radiation and smoking. She pioneered discoveries showing transcription factors inadvertently 'lock in' DNA mistakes, contributing to genomic instability in melanoma and smoking-related cancers. Her work extends to regulatory genomics in Alzheimer's disease and protein engineering for DNA-binding specificity. Publication Trends Analysis of her 2021-2025 publications reveals three dominant themes: (1) Mechanistic studies of transcription factor binding and UV-induced DNA damage in cancer genomes, (2) Computational modeling of cooperative DNA-binding and mutation patterns, and (3) Translational applications in cancer driver identification and protein design. Her work consistently integrates wet-lab validation with algorithmic innovation, with increasing focus on clinical implications for precision oncology. Grant Leadership Dr. Gordan directs multiple major federally funded projects: ETS-family Transcription Factor Mediated Control of Pulmonary Inflammation (NIAID, 2023-2028) NSF/MCB-BSF: Transcription Factor Binding & UV Lesion Accumulation (NSF, 2023-2027) Design/Prioritization of Human Genome Perturbations (NHGRI, 2021-2026) Duke FUNCTION Center: Noncoding Causes of Disease (NHGRI, 2020-2025) Training Program in Bioinformatics/Cancer Immunology (NCI, 2020-2026) Research Infrastructure She leads the Gordan Lab within the Duke Cancer Institute, maintaining strong collaborations with molecular biologists and clinicians. Her team develops open-source computational tools for genomic analysis and participates in Duke's Summer Scholars in Genome Sciences program. Current efforts focus on predicting mutation hotspots in cancer genomes and engineering DNA-binding proteins for therapeutic applications.

• Transcription Factors
• Genomics
• Bioinformatics
• +۳ مورد دیگر

Timo Mueller is a Director at the Institute for Diabetes and Obesity and a W3 Professor at the Walther-Straub Institute for Pharmacology and Toxicology , Ludwig-Maximilians-University Munich (LMU). His work bridges endocrinology , molecular pharmacology , and metabolic disorders to develop personalized preventive and therapeutic strategies for obesity and diabetes. Education: Animal Physiology, Philipps-University Marburg, Germany Ph.D. in Child and Adolescent Psychiatry, University of Duisburg-Essen, Germany (2009) His research on gut hormone-based therapies (e.g., GLP-1, GIP, glucagon) has revolutionized obesity and diabetes treatment. Key contributions include: Establishing GLP-1/GIP co-agonists for weight loss Refuting the role of alternatively activated macrophages in thermogenesis Decoding GIP receptor signaling in the central nervous system Engineering liver-targeted T3 delivery via glucagon His >190 publications span Cell , Nature , and Cell Metabolism . Awards include the Minkowski Award (2023), ERC Consolidator Grant (2022), and Werner-Creutzfeldt Prize (2023). Scientific Awards: Minkowski Award (EASD) - 2023 Werner-Creutzfeldt Prize (DDG) - 2023 Galenus-von-Pergamon Award - 2022 ERC Consolidator Grant (TRUSTED) - 2022 DZD Diabetes Award - 2015 As Head of the Division of Molecular Pharmacology at Helmholtz Munich since 2011 and Director since 2023 , Mueller leads an international team exploring central and peripheral metabolic signaling to combat obesity, diabetes, and comorbidities. Current projects focus on GIP receptor mechanisms and novel hormone-based therapies .

• Endocrinology
• Metabolic Syndrome
• Pharmacology
• +۷ مورد دیگر

Antoine Cerfon is an Associate Professor of Mathematics at the Courant Institute of Mathematical Sciences, New York University. His research focuses on developing advanced numerical methods and asymptotic models for simulating high-temperature, low-density plasmas. Ph.D., Applied Plasma Physics, Massachusetts Institute of Technology, 2010 M.S., Nuclear Science and Engineering, Ecole des Mines de Paris, 2005 B.S., Mathematics and Physics, Ecole des Mines de Paris, 2003 His work addresses computational challenges in plasma physics, with applications to magnetically confined fusion plasmas and particle accelerator beams. The selected publications highlight his contributions to sparse grid algorithms, vortex dynamics in cyclotrons, and high-order solvers for plasma equilibrium problems. Antoine Cerfon is affiliated with the Magneto-Fluid Dynamics Division at the Courant Institute.

• Plasma Physics
• Numerical Analysis
• Applied Mathematics
• +۳ مورد دیگر

Angela Stathopoulos is a Professor in the Division of Biology & Biological Engineering at the California Institute of Technology (Caltech), where she has led her research laboratory for 18 years. She also serves as the Director of the Center for Molecular and Cellular Neuroscience, a position she has held since 2024. Her educational background includes: B.A. from the University of California (1992) Ph.D. from Stanford University (1998), where she studied calcium signaling and calcineurin phosphatase regulated gene expression under Martha Cyert Postdoctoral training at UC Berkeley in Mike Levine's laboratory, using Drosophila as a model system to study transcriptional regulation Dr. Stathopoulos employs a systems-level approach to study embryonic development, integrating cis-regulatory and cell biological data with quantitative measures. Her research focuses on how transcription factors and signaling pathways influence cells to regulate changes in cell shape and form during development. She has made significant contributions to understanding transcriptional regulation, embryonic patterning, and collective cell migration, particularly with the identification of the caudal visceral mesoderm (CVM) as a new collective cell migration model system. Her lab recently incorporated optogenetic approaches to study the dynamic action of transcription factors. The collective body of her recent publications demonstrates a strong focus on developmental mechanisms in Drosophila , with particular emphasis on transcriptional regulation, enhancer function, and cell migration. Her work spans multiple techniques including genetics, biochemistry, live in vivo imaging, and quantitative analysis, reflecting her systems biology approach to developmental questions. Dr. Stathopoulos leads the Stathopoulos Lab at Caltech, which maintains active research programs in embryonic gene expression, enhancer action, fibroblast growth factors, and cell migration. The lab website indicates ongoing investigations into the timing of embryonic gene expression, coordinate action of enhancers, individual functions of fibroblast growth factors, and collective cell migration mechanisms.

• Developmental Biology
• Genetics
• Systems Biology
• +۳ مورد دیگر

Desislava M. Doycheva, PhD, is an Assistant Research Professor in the School of Medicine, jointly affiliated with the Cardiology Division (Department of Medicine) and Physiology Division (Department of Basic Sciences). Her research focuses on molecular mechanisms of neuroprotection in neonatal brain injuries, particularly hypoxic-ischemic encephalopathy (HIE) and germinal matrix hemorrhage. Dr. Doycheva's work explores signaling pathways such as AMPK/Nrf2, microglial polarization, and inflammasome regulation. Her interests include neuroinflammation mitigation, oxidative stress reduction, and developing therapies for stroke and neonatal brain injuries. She utilizes rodent models to investigate pharmacological interventions targeting apoptosis and neurodegeneration. Her recent publications emphasize neuroprotective strategies in neonatal HIE, cerebral hemorrhage, and ischemic stroke, with consistent themes in molecular pathway modulation (e.g., AMPK/Sirt1, AdipoR1, MC1R) and therapeutic timing. Research trends highlight innovations in immunotherapy, delayed recanalization, and biomarker diagnostics. Grants & Projects: Principal Investigator: 'Novel Therapeutic Strategies for Treatment of Neonatal HIE' (American Heart Association, 2020–2023) Post Doctoral Associate: 'Harness Germinal Matrix Hemorrhage' (National Institutes of Health, 2012–2017)

• Neuroscience
• Neuroinflammation
• Neonatal Brain Injury
• +۴ مورد دیگر

Mark Osborn serves as an Associate Professor in the Department of Pediatrics at the University of Minnesota Medical School with three primary institutional roles: Faculty member in the Division of Pediatric Blood and Marrow Transplantation & Cellular Therapy Research Scientist at the Pediatric Blood and Marrow Transplant (BMT) Center Faculty in the Masters Program in Stem Cell Biology His research concentrates on advancing pediatric transplantation therapies through cellular engineering and stem cell applications, specifically targeting hematologic malignancies and genetic disorders in children. This work bridges clinical practice with regenerative medicine approaches to improve engraftment and reduce complications in young transplant recipients. Dr. Osborn operates within the Pediatric BMT Center ecosystem, collaborating on protocols for hematopoietic stem cell transplantation while contributing to graduate education in stem cell sciences. His position connects clinical care with translational research through the university's specialized pediatric oncology infrastructure.

• Pediatric Blood and Marrow Transplantation
• Cellular Therapy
• Stem Cell Biology
• +۳ مورد دیگر

Jenny Schelin is a Senior Lecturer at Lund University's Faculty of Engineering (LTH), holding dual appointments at the Division of Biotechnology and Applied Microbiology within the Department of Chemistry and the Academic Development Unit. She also serves as Programme Director for the Pharmaceutical Technology Master's program and is a Profile Area Member for LTH's Food and Bio initiative. Her research focuses on food safety and food-borne virulence, particularly examining how pathogens like Staphylococcus aureus survive and produce toxins in food matrices and production environments. With expertise in microbial cultivation, detection methods, and risk analysis, her work targets increasing food safety while reducing waste in circular food systems. Recent publications demonstrate strong interdisciplinary connections between microbiology, packaging engineering, and sustainable agriculture. Her 15 most recent publications (2016-2024) reveal consistent focus areas: food safety risk assessment (43% of fingerprint), Staphylococcus aureus research (78%), and food waste reduction (66%). The work spans from fundamental microbiology to applied engineering solutions, with growing emphasis on sustainable packaging and circular food production systems since 2020. Lecturer of the year 2021 Teacher of the year 2019 Excellent Teaching Practitioner (ETP) 2014 Pedagogic Prize from Student Union (TLTH) 2012 As Educational Developer and Programme Director, she coordinates courses in packaging materials and the Erasmus Mundus Master in Food Innovation and Product Design. She chairs Sweden's National Network for Food Microbiology and serves as secretary for 'Livsmedelskollegiet', maintaining active national collaborations with food companies and international research partnerships. Current projects include FORCE (Center for Food Resilience), Siametics (sialic acid derivatives research), and Fermented Food innovation environments.

• Food Safety
• Food-Borne Virulence
• Microbial Activity in Food Matrices
• +۴ مورد دیگر

Professor Prokar Dasgupta serves as Chair in Robotic Surgery & Honorary Consultant Urological Surgeon at King's College London's School of Medicine, specifically within the Peter Gorer Department of Immunobiology. He is a pioneering figure in robotic urological surgery in the UK and serves as Editor-in-Chief of the British Journal of Urology International (BJUI) since 2013. As theme lead for Experimental Surgery within King's Health Partners, he oversees significant translational research initiatives within one of the UK's largest Academic Health Sciences Centers. Professor Dasgupta's research spans multiple cutting-edge domains in urological surgery. His primary focus includes robotics in urology with scientific evaluation of procedures, stem cell and cell-targeted therapies for prostate and bladder cancer, bladder physiology research focusing on receptors like TRPV1 and P2X3, and innovative applications of botulinum toxin for overactive bladders. His work integrates engineering principles with clinical practice, developing mechatronic sensors, augmented reality systems, and 3D planning tools to enhance robotic surgical precision. His research group employs advanced techniques including micro-array technology, real-time PCR, and immunohistochemistry in both human tissues and animal models. Analysis of Professor Dasgupta's recent publications reveals a strong trend toward integrating artificial intelligence with robotic surgery. His work increasingly focuses on surgical workflow analysis, video recognition systems, and overcoming technical limitations in telesurgery. The publications demonstrate his leadership in both clinical applications of robotics and the underlying technological innovations that enable more precise surgical interventions. His research bridges engineering, computer science, and clinical urology to address fundamental challenges in surgical practice. His scientific recognition includes the prestigious Karl Storz-Harold Hopkins Golden Telescope award from the British Association of Urological Surgeons for significant contributions to urology, along with multiple awards for educational contributions including Best Oral Presentations and Best Posters in surgical education. He has been consistently recognized as one of BJUI's top reviewers. Professor Dasgupta has secured approximately £70 million through 36 research grants from major funding bodies including EUFP7, MRC, MS Society, and BUF. He leads a 28-strong multidisciplinary team comprising basic scientists, engineers, and clinician-scientists at King's College London. His supervisory role extends across numerous PhD students and research fellows, contributing to the 84 PhD students supervised by the 41 principal investigators within his division. His educational contributions include serving as tutor for MSc and FRCS (Urol) courses and as an examiner for the University of London. His research environment includes active collaboration with the Wellcome/EPSRC Centre for Medical Engineering and leadership in several major projects including AI-driven surgical skills acquisition, international AI research ecosystems, and innovative prostate cancer treatment trials. His laboratory work integrates robotics, imaging technology, and molecular biology to advance precision surgery in urological oncology.

• Robotic Surgery in Urology
• Stem Cell Therapies for Prostate and Bladder Cancer
• Bladder Physiology
• +۷ مورد دیگر

Sean C. Murphy, MD, PhD is an Adjunct Associate Professor in Microbiology and Associate Professor in Laboratory Medicine at the University of Washington School of Medicine. He serves as Assistant Director of Clinical Microbiology and holds key leadership positions including Director of the Clinical Microbiology Division at Seattle Children's Hospital and Director of the Malaria Molecular Diagnostic Laboratory. His work bridges clinical microbiology, diagnostic development, and malaria research. Dr. Murphy earned his MD and PhD in Microbiology/Immunology from Northwestern University Feinberg School of Medicine (2001-2008), a Post-graduate Diploma in African Studies with Honors from the University of Cape Town (2000), and a BS in Microbiology with Honors from Iowa State University (1996-1999). He completed his Clinical Pathology Residency and served as Chief Resident in the Department of Laboratory Medicine at the University of Washington (2008-2011). Dr. Murphy's research program focuses on the immune response to complex infectious diseases, particularly malaria infection by Plasmodium parasites. His laboratory develops novel high-throughput T cell screening technologies to study poly-specific T cell repertoires induced by Plasmodium sporozoites using mouse models. The group explores synthetic biology-based T cell vaccines and novel methods to induce broadly protective immune responses against malaria. In collaboration with the Seattle Biomed Malaria Clinical Trials Center, Dr. Murphy conducts controlled human malaria infection studies to identify effective drug and vaccine candidates. His recent publications demonstrate a strong focus on malaria immunology, vaccine development, and diagnostic test improvement. The research spans from basic science investigations of Plasmodium liver stage development to clinical trials of monoclonal antibodies for malaria prevention and epidemiological studies of malaria transmission. His work shows increasing collaboration across disciplines including immunology, molecular biology, epidemiology, and clinical medicine. Dr. Murphy serves as a clinical investigator in Phase I/II studies at the Seattle Malaria Clinical Trials Center, the only West Coast-based controlled human malaria infection facility purpose-built in the US. His quantitative reverse transcription PCR assays for malaria detection are recognized as some of the most sensitive and robust molecular diagnostic assays worldwide, allowing detection of malaria parasites 3-4 days earlier than conventional blood smears. He is actively involved in promoting quality improvement initiatives for external quality assurance among a network of controlled human malaria infection centers across the US, Europe, Africa, and Australia. His work extends beyond malaria to include prosthetic joint infections, burn injury recovery, and age-friendly care for older adults, demonstrating a broad commitment to improving health outcomes through diagnostic excellence and translational research.

• Malaria
• Immunology
• Vaccines
• +۵ مورد دیگر

Urban Gullberg is a Professor at Lund University , affiliated with the Faculty of Medicine and the Division of Hematology and Clinical Immunology . He leads the research team on Transcriptional mechanisms for the Wilms’ tumor gene 1 (WT1) oncoprotein at the Lund University Cancer Centre (LUCC), focusing on the role of WT1 in leukemia pathogenesis. Research areas: Genome-wide binding of WT1 isoforms/mutants, transcriptional repression of tumor suppressors (e.g., IRF8), and mechanisms of leukemic cell proliferation. Methods: ChIP-Seq, promoter reporter assays, molecular profiling, and computational deconvolution of gene expression. Key findings: WT1 mutations disrupt transcriptional regulation, contributing to leukemia; identification of co-factors like ZNF224 and therapeutic targets. His work aligns with UN Sustainable Development Goals for cancer research. He supervises PhD students and participates in educational activities related to medical cell biology and targeted therapies.

• Cancer and Oncology
• Hematology
• Transcriptional Regulation
• +۳ مورد دیگر